SomaGenics LogoSANTA CRUZ, Calif., Dec. 18, 2014 /PRNewswire/ — SomaGenics has recently been awarded $2,275,000 in Small Business Innovation Research (SBIR) grants from the NIH to further develop and expand its RNA-based technologies in the areas of wound healing, hepatitis delta virus (HDV) therapeutics, microRNA (miRNA) expression profiling, and next-generation sequencing.

SomaGenics’ wound healing program is focused on treatment of chronic wounds of diabetics. These wounds, frequently occurring on the feet, are the major reason for amputations in the diabetic population and represent a large unmet medical need. SomaGenics’ new NIH funds, in the form of a Phase II SBIR grant, will [click to continue…]


Product innovation and the development of high-qualitative assays are the need of the hour

LONDON, Sept. 4, 2013 /PRNewswire/ — Rapid growth in microRNA (miRNA) research over the past two years, owing to its diagnostic and therapeutic potential, has fueled development in the global miRNA tools and services market. Of the various miRNA technologies, which include quantitative real-time polymerase chain reaction (qRT PCR), microarrays and functional tools, qRT PCR remains the fastest-growing, while microarray is gradually being replaced by next-generation sequencing platforms.

New analysis from Frost & Sullivan (http://www.frost.com/prod/servlet/svcg.pag/HCLS), Global Analysis of MicroRNA Tools and Services Market, finds that the tools side of the market earned revenues of $110.0 million in 2012 and estimates this to more than double to reach $247.7 million in 2017. The US contributed to about 47% of the revenue followed by 36.7% from Europe, while leaving the rest to APAC and ROW. The miRNA services market earned revenues of $35.1 million in 2012 and this is expected to grow to $63.3 million in 2017. The end users covered are academic and research institutes, core facilities, and pharmaceutical and biotech companies.

The growth of therapeutic and diagnostic enterprises, higher research funding and increased outsourcing to contract research organizations in the US will present immense opportunities for the miRNA tools and services market. At the same time, [click to continue…]


Life Technologies offers 2 TaqMan® qPCR grants

by Christoph on October 5, 2011

in News

Life Technologies has 2 TaqMan® qPCR consumables grants available for European research teams*. You have the opportunity to make your project come to life with a grant of either 10,000 or 5,000 euros*.

To apply for the grant you will need to tell Life Technologies about a specific challenge you would like to tackle, what you aim to achieve and outline your motivation for pursuing your study.

Applications will be accepted for a very limited time. Pre-registration is open now. If you would like to pre-register for the TaqMan® Grant please visit www.taqmangrant.com

*Please see Terms and Conditions, available on the TaqMan® Grant website for country eligibility and further details.

Incoming search terms for this article:


MANSFIELD, Mass., Aug. 23, 2011 /PRNewswire/ — PrimeraDx today announced the launch of the ICEPlex® system, the only instrument on the market used for simultaneous detection and quantification of disparate target types, such as mRNA, miRNA, SNPs and DNA“We are excited to have launched the ICEPlex, a quantitative multiplex PCR platform,” stated President and CEO Matthew McManus, MD, PhD.   “No longer will users have to rely on semi-quantitative multiplex solutions.  The ability to take one slice of tissue, extract the nucleic acids, and in one well, in parallel, look at mRNA expression, microRNA expression and SNPs is very powerful.”

PrimeraDx has developed an open platform enabling clinical labs to easily develop cost-effective, high impact molecular diagnostic tests.  The ICEPlex instrument has already been placed with a number of key accounts, including large academic research centers, reference laboratories and bio-pharmaceutical companies.   The ICEPlex instrument has a simple workflow and comes with on-board software for assay design, data analysis and reporting.

“It is very exciting to have this innovative platform from PrimeraDx.  As far as I know, this is the only platform that allows you to assay multiple target types, like mRNA, miRNA and SNPs, in a single well,” commented Andrew Schade, MD, PhD, Senior Director of [click to continue…]

Incoming search terms for this article:


Outsourcing your RNA

by Chris on September 30, 2010

in Publications

RNA expression analysis can be acomplished by microarrays, next-gen sequencing, in situ hybridization or qRT-PCR, but not all investigators have these capabilities in their own labs. Whether constrained by space, infrastructure, know-how, or time, many have no choice but to outsource these types of analyses to others. Often, that means employing a university core facility. But some elect to go off campus altogether, enlisting commercial service providers instead.  Here are some accounts of outsourcing experiences by a few RNA researchers. (read more… )


MicroRNAs as Potential Biomarkers in Cancer and Heart Disease

October 30, 2009

Heart disease and cancer represent the number one and number two killer diseases in developed countries. Identifying biomarkers to detect these and other diseases at early stages remains an important research goal and researchers are scrambling for ways to identify contributing factors to the pathogenesis of diseased cells in the body.  In recent years, research […]

Read the full article →

qPCR Congress 2009

April 29, 2009

During a recent analyst briefing titled “From Stem Cells and Cancer to Diagnostics and Therapeutics; microRNAs-Small Molecules with a Big Impact” Frost & Sullivan presented data about the US miRNA market. According to these data the qRT-PCR segment represents the largest segment in the overall miRNA market (37.7%). It is followed by the microarray segment […]

Read the full article →